Liver Disease News and Research

RSS

The liver is one of the largest solid organs of the body. It is located in the upper right part of the abdomen. Most of the organ lies under cover of the rib cage.

Skin cell to liver cell shows promise for genetic liver disease

In a new scientific breakthrough, researchers have taken skin cells from a patient with liver disease and turned them into replacement liver cells. Although the procedure is years before it can be used in humans, but if approved, it could launch a new era of personalized therapies for serious genetic disorders.

13 Oct 2011

Isis designates ISIS-AATRx candidate in collaboration with GSK

Isis Pharmaceuticals, Inc. announced today that it has designated the second development candidate, ISIS-AATRx, in its collaboration with GlaxoSmithKline

12 Oct 2011

CHOP, Albert Einstein College of Medicine to study genetics of conotruncal defects

The Eunice Kennedy Shriver National Institute of Child Health & Human Development, part of the National Institutes of Health, has awarded researchers at Albert Einstein College of Medicine of Yeshiva University and collaborators at the Children's Hospital of Philadelphia (CHOP) a five-year, $6.7 million grant to study the genetics of both rare and common congenital heart abnormalities known as conotruncal defects.

12 Oct 2011

Vertex announces availability of INCIVEK to treat hepatitis C in Canada

Vertex Pharmaceuticals Incorporated announced today that INCIVEK (telaprevir) tablets are now available in Canada for people with genotype 1 chronic hepatitis C with compensated liver disease, including cirrhosis.

11 Oct 2011

VGX International, Inovio partner to co-develop SynCon vaccines for hepatitis B and C infections

Inovio Pharmaceuticals, Inc., a leader in the development of synthetic vaccines against cancers and infectious diseases, announced today that it has entered into a product development collaboration agreement with its affiliate, VGX International Inc., to co-develop Inovio's SynCon therapeutic vaccines for hepatitis B and C infections.

10 Oct 2011

Merck receives FDA approval for JUVISYNC to treat type 2 diabetes

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved JUVISYNC(sitagliptin and simvastatin), a new treatment for type 2 diabetes that combines the glucose-lowering medication sitagliptin, the active component of JANUVIA (sitagliptin), with the cholesterol-lowering medication ZOCOR.

10 Oct 2011

Santaris Pharma to report new clinical data from miravirsen Phase 2a study on HCV

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA and mRNA-targeted therapies, today announced the Company will report new clinical data results from the miravirsen Phase 2a proof-of-concept study to treat patients infected with the Hepatitis C virus (HCV) in a late-breaking oral presentation session at the American Association for the Study of Liver Diseases (AASLD) 2011 annual meeting.

4 Oct 2011

Bristol-Myers to present abstracts on research in liver disease at The Liver Meeting 2011

Bristol-Myers Squibb Company announced today that 22 abstracts on the Company's research in liver disease have been accepted for presentation at The Liver Meeting 2011, the 62nd annual meeting of the American Association for the Study of Liver Diseases, in San Francisco, November 4 - 8.

1 Oct 2011

New AAOS guideline recommends how to reduce DVT, PE after joint replacement surgery

An updated clinical practice guideline released last week by the American Academy of Orthopaedic Surgeons (AAOS) Board of Directors recommends how to reduce the likelihood of blood clots after hip or knee replacement surgery, procedures that more than 800,000 Americans undergo each year. The new guideline suggests use of preventive treatments and advises against routinely screening patients after surgery using ultrasound imaging.

1 Oct 2011

New analyses from Phase III studies of VICTRELIS to be presented at AASLD 2011

Merck, known as MSD outside of the United States and Canada, announced today that several new analyses from Phase III studies of VICTRELIS (boceprevir), the company's first-in-class, oral hepatitis C virus NS3/4A protease inhibitor will be presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases.

1 Oct 2011

Vertex announces abstracts from hepatitis C program to be presented at The Liver Meeting

Vertex Pharmaceuticals Incorporated today announced that abstracts from its hepatitis C program, including two late-breaking posters from studies of INCIVEK (telaprevir) tablets and VX-222, were accepted for presentation at The Liver Meeting, the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco, November 4-8, 2011.

1 Oct 2011

Galectin posts new corporate video on galectin-inhibiting therapeutics to treat fibrosis and cancer

Galectin Therapeutics Inc. today announced that it posted a new corporate presentation video to its website, www.galectintherapeutics.com, that highlights the Company's leadership position in developing galectin-inhibiting therapeutics to treat fibrosis and cancer.

30 Sep 2011

Oral steroid users twice as likely to have severe vitamin D deficiency

People taking oral steroids are twice as likely as the general population to have severe vitamin D deficiency, according to a study of more than 31,000 children and adults by scientists at Albert Einstein College of Medicine of Yeshiva University.

30 Sep 2011

AASLD publishes updated practice guidelines on hepatitis C

On Monday, September 26, 2011, the American Association for the Study of Liver Diseases published online at its journal Hepatology's website an update to its practice guidelines for hepatitis C – "An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases."

29 Sep 2011

Long-term morbidity and mortality of NAFLD patients with advanced fibrosis, cirrhosis

Patients with non-alcoholic fatty liver disease (NAFLD) with advanced fibrosis or cirrhosis have a lower incidence of liver-related complications and hepatocellular carcinoma (HCC) than patients infected with hepatitis C virus (HCV), according to the prospective study published in the October issue of Hepatology, a journal of the American Association for the Study of Liver Diseases.

28 Sep 2011

Liver transplantation candidates without HCC derive greater survival benefit from LDLT

New research shows liver transplantation candidates without hepatocellular carcinoma (HCC) derive a greater survival benefit from a living donor liver transplant (LDLT) than waiting for a deceased donor liver transplant.

28 Sep 2011

Men over 75 with prostate cancer are being undertreated: Study

It's an ongoing debate: Should men over a certain age be treated for prostate cancer? Should these patients be submitted to treatments that may result in significant side effects if they may not live very much longer?

27 Sep 2011

Percutaneous hepatic perfusion extends survival time for melanoma patients

Melanoma of the eye frequently spreads to the liver and, once this has happened, there is no effective treatment and patients die within an average of two to four months. Only about one in ten patients live for a year. Now, final results from a phase III study have demonstrated that a new treatment significantly extends the time patients can live without the disease progressing.

26 Sep 2011

ECDA welcomes UN High Level Meeting on Non Communicable Diseases

The European Chronic Disease Alliance (ECDA) welcomes the UN High Level Meeting on Non Communicable Diseases (NCDs) to address the world biggest killers. "It is a memorable day in the history of public health. Discussing non communicable diseases at the UN table gives a strong sense of the burden it represents to human kind and the recognition that NCDs is a challenge for all nations in the world", declared Professor Michel Komajda, President of the European Society of Cardiology, an active member of the ECDA.

26 Sep 2011

Researchers discover how a novel type of antibody works against pneumococcal bacteria

Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered how a novel type of antibody works against pneumococcal bacteria.

23 Sep 2011

Liver Disease News and Research

Further Reading

Skin cell to liver cell shows promise for genetic liver disease

Isis designates ISIS-AATRx candidate in collaboration with GSK

CHOP, Albert Einstein College of Medicine to study genetics of conotruncal defects

Vertex announces availability of INCIVEK to treat hepatitis C in Canada

VGX International, Inovio partner to co-develop SynCon vaccines for hepatitis B and C infections

Merck receives FDA approval for JUVISYNC to treat type 2 diabetes

Santaris Pharma to report new clinical data from miravirsen Phase 2a study on HCV

Bristol-Myers to present abstracts on research in liver disease at The Liver Meeting 2011

New AAOS guideline recommends how to reduce DVT, PE after joint replacement surgery

New analyses from Phase III studies of VICTRELIS to be presented at AASLD 2011

Vertex announces abstracts from hepatitis C program to be presented at The Liver Meeting

Galectin posts new corporate video on galectin-inhibiting therapeutics to treat fibrosis and cancer

Oral steroid users twice as likely to have severe vitamin D deficiency

AASLD publishes updated practice guidelines on hepatitis C

Long-term morbidity and mortality of NAFLD patients with advanced fibrosis, cirrhosis

Liver transplantation candidates without HCC derive greater survival benefit from LDLT

Men over 75 with prostate cancer are being undertreated: Study

Percutaneous hepatic perfusion extends survival time for melanoma patients

ECDA welcomes UN High Level Meeting on Non Communicable Diseases

Researchers discover how a novel type of antibody works against pneumococcal bacteria

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News